Natural Killer Cell Receptors and Endometriosis: A Systematic Review

Int J Mol Sci. 2022 Dec 25;24(1):331. doi: 10.3390/ijms24010331.

Abstract

Endometriosis is a chronic inflammatory disorder, characterized by the presence of endometrial cells outside the uterine cavity. An increasing number of studies correlate the immune system with endometriosis, particularly NK receptors (NKR), which have been suggested to play an essential role in the pathogenesis of the disease. This systematic review aims to enlighten the role of NKR in endometriosis. A literature search was performed independently by two reviewers, to identify studies assessing the role of NKR in endometriosis. In total, 18 studies were included. Endometriosis pathogenesis seems to be marked by the overexpression of NK inhibitor receptors (KIRS), namely, CD158a+, KIR2DL1, CD94/NKG2A, PD-1, NKB1, and EB6, and inhibiting ligands such as PD-L1, HLA-E, HLA-G, and HLA-I. Concurrently, there is a decrease in NK-activating receptors and natural cytotoxicity receptors (NCRs), such as NKp46, NKp30, and NKG2D. The immune shift from NK surveillance to NK suppression is also apparent in the greater relative number of ITIM domains compared with ITAM domains in NKRs. In conclusion, NK receptor activity seems to dictate the immunocompetency of women to clear endometriotic cells from the peritoneal cavity. Future research could explore NKRs as therapeutic targets, such as that which is now well established in cancer therapy through immunotherapy.

Keywords: NK inhibition; NK receptors; NK suppression; ectopic endometrium; endometrioma; endometriosis; immune dysfunction; natural killer cells (NK cells).

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Endometriosis* / pathology
  • Endometrium / pathology
  • Female
  • Humans
  • Killer Cells, Natural*
  • Receptors, Natural Killer Cell

Substances

  • Receptors, Natural Killer Cell

Grants and funding

This work in the context of the “Women’s Health and Maternal & Fetal Research Group” was partially co-financed by Hospital da Luz Lisboa under the initiative “Luz Investigação”.